180 related articles for article (PubMed ID: 2178755)
1. New antiemetic drugs.
Sanger GJ
Can J Physiol Pharmacol; 1990 Feb; 68(2):314-24. PubMed ID: 2178755
[TBL] [Abstract][Full Text] [Related]
2. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
Rizk AN; Hesketh PJ
Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
[TBL] [Abstract][Full Text] [Related]
3. Physiology of chemotherapy-induced emesis and antiemetic therapy. Predictive models for evaluation of new compounds.
Veyrat-Follet C; Farinotti R; Palmer JL
Drugs; 1997 Feb; 53(2):206-34. PubMed ID: 9028742
[TBL] [Abstract][Full Text] [Related]
4. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
Goodman M
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
[TBL] [Abstract][Full Text] [Related]
5. Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs.
Bountra C; Gale JD; Gardner CJ; Jordan CC; Kilpatrick GJ; Twissell DJ; Ward P
Oncology; 1996 Jun; 53 Suppl 1():102-9. PubMed ID: 8692545
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron, a new antiemetic therapy for oncology. An overview.
Lip H
Scand J Gastroenterol Suppl; 1990; 178():55-61. PubMed ID: 2148983
[TBL] [Abstract][Full Text] [Related]
7. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
8. [Value of 5-HT3 receptor antagonists, particularly as anti-emetic drugs].
Lechat P
Ann Pharm Fr; 1991; 49(6):307-16. PubMed ID: 1842169
[TBL] [Abstract][Full Text] [Related]
9. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
de Wit R; Aapro M; Blower PR
Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
[TBL] [Abstract][Full Text] [Related]
10. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
Herrstedt J
Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
[TBL] [Abstract][Full Text] [Related]
11. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
12. Management of vomiting associated with cytotoxic therapy.
Jones AL; Cunningham D
Br J Hosp Med; 1991 Feb; 45(2):85-8. PubMed ID: 2018889
[TBL] [Abstract][Full Text] [Related]
13. [Prophylaxis of chemotherapy-induced vomiting and nausea].
Tóth J; Szántó J
Magy Onkol; 2008 Dec; 52(4):391-4. PubMed ID: 19068468
[TBL] [Abstract][Full Text] [Related]
14. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
Schwartzberg LS
Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
Aapro M; Johnson J
Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
[TBL] [Abstract][Full Text] [Related]
17. State of the Art Antiemetic Therapy for Cancer Patients.
Lau TK; Yip CH; Yeo W
Curr Oncol Rep; 2016 Jan; 18(1):2. PubMed ID: 26694923
[TBL] [Abstract][Full Text] [Related]
18. New directions in managing chemotherapy-related emesis.
Krasnow SH
Oncology (Williston Park); 1991 Sep; 5(9 Suppl):19-24. PubMed ID: 1836346
[TBL] [Abstract][Full Text] [Related]
19. Looking beyond 5-HT(3) receptors: a review of the wider role of serotonin in the pharmacology of nausea and vomiting.
Johnston KD; Lu Z; Rudd JA
Eur J Pharmacol; 2014 Jan; 722():13-25. PubMed ID: 24189639
[TBL] [Abstract][Full Text] [Related]
20. Management of nausea and vomiting caused by anticancer drugs: state of the art.
Pisters KM; Kris MG
Oncology (Williston Park); 1992 Feb; 6(2 Suppl):99-104. PubMed ID: 1532744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
